CLLS logo

CLLSCellectis

$3.11
$0.02
(0.65%)
Today
Updated: 01:23 PM EDT
Reported EarningsMay 11
Mkt Cap$223.49M
Vol42,772.00
News
all
press releases
Cellectis (CLLS) to Release Quarterly Earnings on Monday
Cellectis (NASDAQ:CLLS) will be releasing its Q1 2026 earnings after the market closes on Monday, May 11. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-11-cellectis-sa-stock...
MarketBeat
News Placeholder
More News
News Placeholder
Cellectis (NASDAQ:CLLS) Stock Price Crosses Below 200 Day Moving Average - Time to Sell?
Cellectis (NASDAQ:CLLS) Stock Price Crosses Below 200 Day Moving Average - Here's What Happened...
MarketBeat
News Placeholder
Cellectis (NASDAQ:CLLS) Shares Pass Below 200-Day Moving Average - Time to Sell?
Cellectis (NASDAQ:CLLS) Stock Price Passes Below 200 Day Moving Average - Should You Sell...
MarketBeat
News Placeholder
Cellectis (NASDAQ:CLLS) Given Market Outperform Rating at Citizens Jmp
Citizens Jmp reiterated a "market outperform" rating and issued a $8.00 price objective on shares of Cellectis in a research note on Tuesday...
MarketBeat
News Placeholder
Cellectis S.A. (NASDAQ:CLLS) Receives Consensus Recommendation of "Moderate Buy" from Analysts
Shares of Cellectis S.A. (NASDAQ:CLLS - Get Free Report) have been given an average rating of "Moderate Buy" by the five ratings firms that are presently covering the stock, Marketbeat Ratings...
MarketBeat
News Placeholder
Allogene Arbitration Victory Pressures Cellectis Shares Tuesday
Cellectis shares fell after Allogene cited a favorable arbitration ruling confirming control of cema-cel and outlining key CAR-T milestones.read more...
Benzinga
News Placeholder
Cellectis (NASDAQ:CLLS) Share Price Crosses Above Fifty Day Moving Average - Here's Why
Cellectis (NASDAQ:CLLS) Stock Passes Above Fifty Day Moving Average - Should You Sell...
MarketBeat
News Placeholder
Why Cellectis Stock Is Trading Higher Today
Cellectis reports strong Nature Communications data showing CssDNA boosts non-viral gene insertion efficiency and supports long-term therapeutic potential.read more...
Benzinga
News Placeholder
Cellectis (NASDAQ:CLLS) Shares Cross Above Fifty Day Moving Average - Should You Sell?
Cellectis (NASDAQ:CLLS) Stock Crosses Above 50 Day Moving Average - Here's Why...
MarketBeat
News Placeholder
Cellectis (NASDAQ:CLLS) Posts Earnings Results, Beats Estimates By $0.11 EPS
Cellectis (NASDAQ:CLLS - Get Free Report) posted its quarterly earnings data on Friday. The biotechnology company reported $0.01 earnings per share (EPS) for the quarter, beating analysts' consensus...
MarketBeat
<
1
2
...
>

Advertisement|Remove ads.